Concurrent temozolomide (TMZ) and radiotherapy is the new standard of care for patients with newly diagnosed glioblastoma. In 51 consecutive patients treated according to this regimen, 7 patients (14%) manifested surgically confirmed early necrosis without evidence of recurrent tumor. This observation suggests that daily TMZ may represent a potent radiosensitizing regimen.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11060-006-9241-y | DOI Listing |
Publication Analysis
Top Keywords
early necrosis
8
necrosis concurrent
4
concurrent temodar
4
temodar radiotherapy
4
patients
4
radiotherapy patients
4
patients glioblastoma
4
glioblastoma concurrent
4
concurrent temozolomide
4
temozolomide tmz
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!